These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30341703)

  • 1. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis.
    Yu C; Jin S; Wang Y; Jiang N; Wu C; Wang Q; Tian X; Li M; Zeng X
    Clin Rheumatol; 2019 Mar; 38(3):727-738. PubMed ID: 30341703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.
    Jurgens MS; Welsing PM; Jacobs JW
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S56-63. PubMed ID: 23078808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
    Cárdenas MJ; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2017 Oct; 37(10):1701-1708. PubMed ID: 28597307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.
    Iannone F; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Caporali R; Codullo V; Ferraccioli G; Gremese E; Carletto A; Giollo A; Govoni M; Bergossi F; Galeazzi M; Cantarini L; Salaffi F; Di Carlo M; Bazzani C; Pellerito R; Sebastiani M; Ramonda R; Lapadula G
    Clin Rheumatol; 2016 Nov; 35(11):2649-2656. PubMed ID: 27418051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
    Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
    Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.
    Ward MM; Madanchi N; Yazdanyar A; Shah NR; Constantinescu F
    Arthritis Res Ther; 2023 Nov; 25(1):222. PubMed ID: 37986101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis.
    Galvao TF; Zimmermann IR; da Mota LM; Silva MT; Pereira MG
    Clin Rheumatol; 2016 Jul; 35(7):1659-68. PubMed ID: 27107756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
    Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
    Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis.
    Khader Y; Beran A; Ghazaleh S; Lee-Smith W; Altorok N
    Clin Rheumatol; 2022 Dec; 41(12):3615-3627. PubMed ID: 35974226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
    Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
    Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.